lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Low IFN-γ Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients

26 Pages Posted: 28 Apr 2022

See all articles by Marion Cremoni

Marion Cremoni

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Jonathan Allouche

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Daisy Graça

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Kevin Zorzi

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Céline Fernandez

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Maxime Teisseyre

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Sylvia Benzaken

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Caroline Ruetsch-Chelli

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Vincent LM Esnault

Nice University Hospital - Department of Nephrology, Dialysis and Transplantation

Jean Dellamonica

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

michel Carles

Université Cote d'Azur - Nice University Hospital

Jérôme Barrière

Saint Jean Hospital - Department of Medical Oncology

Vesna Brglez

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

Barbara Seitz-Polski

Université Côte d'Azur - Clinical Research Unit Côte d’Azur

More...

Abstract

Background: The SARS-CoV-2 infection has spread rapidly around the world causing millions of deaths. Several treatments can reduce mortality and hospitalization. However, their efficacy depends on the choice of the molecule and the precise timing of its administration to ensure viral clearance and avoid a deleterious inflammatory response.

Methods: In 115 subjects at an early stage of SARS-CoV-2 infection (within the first five days) or within one month prior to infection, we studied IFN-γ response, assessed by a functional immunoassay, as a predictive biomarker for the risk of hospitalization.

Findings: We found that individuals with IFN-γ levels below 15 IU/mL were 6·57-times more likely to be hospitalized than those with higher values (p<0·001). As confirmed by multivariate analysis, low IFN-γ levels, age >65 years, and no vaccination were independently associated with hospitalization.

Interpretation: Early analysis of the IFN-γ response in a contact or recently infected subject with SARS-CoV-2 could predict the individual risk of hospitalization and thus help the clinician to choose the appropriate treatment avoiding severe forms of infection and hospitalization.

Funding: French Ministry of Health.

Declaration of Interest: The authors declare no conflict of interest.

Ethical Approval: The participants included in this study were extracted from three prospective monocentric cohorts at Nice University Hospital: (i) patients recruited during an infectious diseases or emergency room consultation following COVID-19 symptoms, or a contact case between March 2020 and January 2022 (CovImmune 1 study, NCT04355351); (ii) patients recruited by partner laboratories during a positive RT-PCR for SARS-CoV-2, performed in the context of suggestive symptomatology, contact case, or health pass, between August 2021 and November 2021 (CovImmune 1 study, NCT04355351); (iii) individuals monitored systematically and periodically since July 2020 as part of an epidemiological study in the context of COVID-19 (CovImmune 2 study, NCT04429594).

Keywords: SARS-CoV-2, viral infection, IFN-γ, functional immunoassay, predictive biomarker, personalized medicine

Suggested Citation

Cremoni, Marion and Allouche, Jonathan and Graça, Daisy and Zorzi, Kevin and Fernandez, Céline and Teisseyre, Maxime and Benzaken, Sylvia and Ruetsch-Chelli, Caroline and Esnault, Vincent LM and Dellamonica, Jean and Carles, michel and Barrière, Jérôme and Brglez, Vesna and Seitz-Polski, Barbara, Low IFN-γ Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients. Available at SSRN: https://ssrn.com/abstract=4095756 or http://dx.doi.org/10.2139/ssrn.4095756

Marion Cremoni (Contact Author)

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Jonathan Allouche

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Daisy Graça

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Kevin Zorzi

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Céline Fernandez

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Maxime Teisseyre

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Sylvia Benzaken

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Caroline Ruetsch-Chelli

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Vincent LM Esnault

Nice University Hospital - Department of Nephrology, Dialysis and Transplantation ( email )

Nice
France

Jean Dellamonica

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Michel Carles

Université Cote d'Azur - Nice University Hospital

Jérôme Barrière

Saint Jean Hospital - Department of Medical Oncology ( email )

France

Vesna Brglez

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )

Barbara Seitz-Polski

Université Côte d'Azur - Clinical Research Unit Côte d’Azur ( email )